


STOCK2S-26016

Cat. No.:	HY-112143		
CAS No.:	332922-63-1		
Molecular Formula:	C ₂₀ H ₁₉ N ₃ O ₂		
Molecular Weight:	333.38		
Target:	Ser/Thr Protease		
Pathway:	Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
	In solvent	-80°C	6 months
		-20°C	1 month



BIOLOGICAL ACTIVITY

Description	STOCK2S-26016 is a WNK signalling inhibitors. STOCK2S-26016 inhibits WNK4 and WNK1 with IC ₅₀ s of 16 μM and 34.4 μM, respectively. STOCK2S-26016 has potential for antihypertensive research ^[1] .
IC ₅₀ & Target	IC ₅₀ : 16 μM (WNK4); 34.4 μM (WNK1) ^[1]
In Vitro	<p>STOCK2S-26016 (10 and 30 minutes) blocks the effect of L-NAME on phosphorylated sodium-chloride cotransporter (NCC) in mDCT cells^[2].</p> <p>STOCK2S-26016 (25-200 μM) drastically and dose-dependently reduces the phosphorylation of STE20/SPS1-related proline/alanine-rich protein kinase (SPAK) and NCC in mpkDCT cells^[1].</p> <p>STOCK2S-26016 (50-200 μM) drastically and dose-dependently reduces the phosphorylation of SPAK and Na/K/Cl cotransporter 1 (NKCC1) in MOVAS cells^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

REFERENCES

- [1]. Takayasu M, et, al. Chemical library screening for WNK signalling inhibitors using fluorescence correlation spectroscopy. *Biochem J.* 2013 Nov 1; 455(3): 339-45.
- [2]. Conghui W, et, al. Low dose L-NAME induces salt sensitivity associated with sustained increased blood volume and sodium-chloride cotransporter activity in rodents. *Kidney Int.* 2020 Jun 24; S0085-2538(20)30703-1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA